28 Aug 2016
TaiGen Biotechnology Company, Limited (TaiGen) has signed an exclusive licensing agreement with Productos Científicos S.A. de C.V. (PC), a leading Mexican pharmaceutical company, to develop and commercialize Taigexyn (nemonoxacin) in Latin America.
Taigexyn is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria.
Under the terms of the agreement, PC will be responsible for the development, registration and commercialization of Taigexyn in the territory and assume all associated costs. The territory includes Mexico, Brazil, Colombia, Peru, Uruguay, Paraguay, Bolivia, Venezuela, Argentina, Chile, Costa Rica, Honduras, Nicaragua, Panama, Guatemala, El Salvador and Ecuador. In exchange for the exclusive rights, TaiGen will receive an upfront payment and is eligible for additional regulatory and commercial milestones in the future. PC will purchase Taigexyn at a pre-negotiated price from TaiGen for its commercialization in the territory.
In the US, TaiGen have completed two phase 2 studies, one in CAP and the other in diabetic foot infections (DFI). In December 2013, the US FDA granted Taigexyn Qualified Infectious Disease Product (QIDP) and Fast Track designations for CAP and acute bacterial skin and skin structure infections (ABSSSI). TaiGen owns the worldwide patent portfolio of Taigexyn that protects composition, use, and processes until 2029.